Wells Fargo’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$388 Hold
125
﹤0.01% 6418
2025
Q4
$500 Sell
125
-10
-7% -$78 ﹤0.01% 6334
2025
Q3
$1.67K Hold
135
﹤0.01% 6208
2025
Q2
$2.83K Hold
135
﹤0.01% 6162
2025
Q1
$4K Buy
135
+10
+8% +$319 ﹤0.01% 6059
2024
Q4
$4.06K Hold
125
﹤0.01% 6096
2024
Q3
$5.03K Buy
+125
New +$6.69K ﹤0.01% 5914
2022
Q2
Sell
-8
Closed -$2K 6841
2022
Q1
$2K Hold
8
﹤0.01% 6652
2021
Q4
$2K Hold
8
﹤0.01% 6868
2021
Q3
$2K Hold
8
﹤0.01% 6553
2021
Q2
$3K Hold
8
﹤0.01% 6445
2021
Q1
$4K Buy
+8
New +$3.47K ﹤0.01% 6532

Other funds holding CANF

Wells Fargo's CANF Position: Q1 2026 in Review

Wells Fargo held its Can-Fite BioPharma American Depositary Shares (CANF) position steady in Q1 2026 at 125 shares worth $388. The position accounts for ﹤0.01% of the portfolio, ranked #6418.

Wells Fargo first reported a position in CANF in Q1 2021 and has held it in 12 quarters since. The position peaked at $5.03K in Q3 2024. 14 funds tracked by Wall St. Rank hold CANF as of Q1 2026.

  • Wells Fargo held 125 shares of Can-Fite BioPharma American Depositary Shares worth $388 as of Q1 2026.
  • Wells Fargo left its Can-Fite BioPharma American Depositary Shares share count unchanged in Q1 2026.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6418 holding.
  • Wells Fargo first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2021 and has held it in 12 quarters since.
  • Wells Fargo's Can-Fite BioPharma American Depositary Shares position peaked at $5.03K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.